Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 25
Filter
1.
Rio de Janeiro; s.n; 2023. 129 p. ilus.
Thesis in Portuguese | LILACS | ID: biblio-1537766

ABSTRACT

Introdução: O câncer do colo do útero (CCU) acontece em decorrência da infecção crônica e persistente por tipos oncogênicos do papilomavírus humano (HPV) na genitália feminina. Sua incidência ainda é alta em países em desenvolvimento como o Brasil, onde o diagnóstico muitas vezes é realizado em estádios avançados. O HPV 16 é o tipo mundialmente mais comum no CCU. O estudo da associação das diferentes linhagens do HPV 16 à sobrevida global e livre de doença do CCU pode contribuir na compreensão do comportamento das diferentes linhagens do HPV 16 em relação ao prognóstico. Objetivo: Avaliar o prognóstico de mulheres com câncer do colo do útero tratadas em uma Instituição brasileira, em relação às linhagens do HPV16. Métodos: Os dados desta análise são provenientes de uma coorte prospectiva de 334 mulheres com CCU tratadas no INCA (Rio de Janeiro) recrutadas entre julho de 2011 e março de 2014. A identificação das linhagens do HPV 16 foi realizada em amostra do tecido tumoral. A diversidade genética do HPV 16 foi representada por 218 casos da linhagem A, 10 da linhagem B, 10 da linhagem C e 96 da linhagem D. Além das linhagens do HPV 16, a idade, tipo histopatológico, estadiamento e completude de tratamento foram avaliados em relação ao prognóstico do CCU. Resultados: A idade mediana foi de 48 anos. O tipo histopatológico mais frequente foi o carcinoma epidermoide (82,3%), seguido do adenocarcinoma. O estadiamento com doença localmente avançada foi o mais comum nesta amostra, sendo representado por percentuais semelhantes nos estádios II e III (36,2% e 37,7%), seguido do estádio inicial I (19,2%) e pelo estadiamento IV, com doença à distância (6,9%). Apenas 187 mulheres completaram o tratamento. As variáveis idade, tipo histológico, estadiamento e completude de tratamento estiveram associadas com maior risco de morte, o que não ocorreu com a variável linhagem do HPV 16. Em relação à idade, a cada acréscimo de um ano de vida, houve aumento de aproximadamente 1% no risco de morte. Outros tipos histopatológicos (carcinoma pouco diferenciado, adenoescamoso, neuroendócrino e sarcoma) mostraram um maior risco de óbito em relação ao adenocarcinoma. O carcinoma epidermoide também representou maior risco de morte do que no adenocarcinoma, embora sem significância estatística. As mulheres diagnosticadas com estadiamento avançado tiveram maior risco de morte, e as que não completaram o tratamento aumentaram em mais de duas vezes o risco de morrer. Conclusão: Esse estudo não encontrou associação entre as linhagens A, B, C e D do HPV 16 e o prognóstico do CCU.


Introduction: Cervical cancer (CC) occurs as a result of chronic and persistent infection by the oncogenic type of human papillomavirus (HPV) in the female genitalia. Its incidence is still high in developing countries like Brazil, where the diagnosis is often performed in advanced stages. HPV 16 is the most common type in CC worldwide. Studying the association of different HPV 16 lineage with overall and disease-free survival in CC may contribute to understanding the behavior of different HPV 16 lineage in relation to prognosis. Objective: To evaluate the prognosis of women with cervical cancer treated at a Brazilian institution, in relation to HPV16 lineage A, B, C and D. Methods: The data from this analysis are from a prospective cohort of 334 women with CC treated at INCA (Rio de Janeiro) recruited between july 2011 and march 2014. Identification of HPV 16 lineage was performed on a sample of tumor tissue. The genetic diversity of HPV 16 was represented by 218 cases of the A lineage, 10 of the B lineage, 10 of the C lineage and 96 of the D lineage. In addition to the HPV 16 lineages; age, histopathological type, staging and completeness of treatment were evaluated in association with the prognosis of CC. Results: The median age was 48 years. The most frequent histopathological type was squamous cell carcinoma (82.3%), followed by adenocarcinoma. Staging with locally advanced disease was the most common in this sample, being represented by similar percentages in stages II and III (36.2% and 37.7%), followed by initial stage I (19.2%) and by stage IV, with distant disease (6.9%). Only 187 women completed the treatment. The variables age, histological type, staging and completion of treatment were associated with a higher risk of death, which did not occur with the variable HPV 16 lineage. Regarding age, with each increase of one year, there was an increase of approximately 1% in the risk of death. Other histopathological types (poorly differentiated, adenosquamous, neuroendocrine and sarcoma) showed a higher risk of death compared to adenocarcinoma. Squamous cell carcinoma also represented a higher risk of death than adenocarcinoma, although without statistical significance. Women diagnosed with advanced staging had a higher risk of death, and those who did not complete treatment increased their risk of dying by more than twice. Conclusion: This study found no association between HPV 16 lineage A, B, C and D and CC prognosis.


Subject(s)
Humans , Female , Prognosis , Survival , Uterine Cervical Neoplasms , Human papillomavirus 16/genetics
2.
Chinese Journal of Pathology ; (12): 338-343, 2022.
Article in Chinese | WPRIM | ID: wpr-935536

ABSTRACT

Objective: To examine the prevalence and frequencies of human papillomavirus (HPV) genotypes in cervical adenocarcinoma in situ (AIS). Methods: The cases of cervical AIS with concurrent tests of cytology and HPV typing from January 2007 to February 2020 in the Obstetrics and Gynecology Hospital of Fudan University were collected and analyzed. Results: A total of 478 cases of cervical AIS were obtained. The average age of the patients was 39.4 years (range, 19-81 years). The largest age group was 30-39 years (44.8%), followed by 40-49 years (34.7%). Among the 478 patients, 355 underwent high-risk HPV (hrHPV) testing and had a hrHPV-positive rate of 93.8%. Of the 355 patients, 277 also underwent HPV typing and were mostly positive for either or both HPV16 and HPV18 (93.1%), with 55.6% positive for HPV18 and 48.7% positive for HPV16. Among the 478 cases, 266 cases (55.6%) were diagnosed with both AIS and squamous intraepithelial lesion (SIL), while 212 cases (44.4%) were diagnosed with only AIS. Patients infected with HPV16 in the AIS and SIL group significantly outnumbered those in the AIS alone group (P<0.05). Moreover, the rate of positive cytology was 55.9% (167/299 cases), while that of negative cytology was 44.1% (132/299). Among the 109 patients with negative cytology results and co-tested hrHPV, there were 101 HPV-positive cases (92.7%), of which 88 cases were subject to HPV typing and showed an HPV16/18 positive rate of 94.3% (83/88 cases). Conclusions: The combination of HPV typing and cytological screening can maximize the detection rate of cervical AIS, and should continue to be utilized, ideally on a larger scale, in the future.


Subject(s)
Adult , Aged , Aged, 80 and over , Female , Humans , Middle Aged , Young Adult , Adenocarcinoma in Situ/epidemiology , Human papillomavirus 16/genetics , Human papillomavirus 18/genetics , Papillomaviridae/genetics , Papillomavirus Infections/diagnosis , Prevalence , Uterine Cervical Neoplasms/pathology
3.
Chinese Journal of Preventive Medicine ; (12): 165-170, 2022.
Article in Chinese | WPRIM | ID: wpr-935266

ABSTRACT

Objective: To evaluate the performance of point-of-care testing for cervical cancer and precancerous lesions screening. Methods: In September 2020, 197 and 273 women were selected by using simple random sampling method from "self-sampling" cohort and "physician-sampling" cohort established in Xiangyuan county, Shanxi Province, China, respectively. Cervical exfoliated cells were collected by women themselves or gynecologists. All samples were detected by POCT and women with positive result were directly referred for colposcopy. Subsequently, all the samples were detected by careHPV and PCR test. Colposcopy and punch biopsy were performed for women with POCT negative but careHPV or PCR test positive at another visit. Using histopathological diagnosis as the gold standard, we calculated sensitivity, specificity and drew the receiver operating characteristic (ROC) curves. The accuracy of POCT was analyzed and compared to that of careHPV and conventional PCR test in cervical cancer and precancerous lesions screening. Results: The median (Q1 , Q3) age of 470 women was 51 (45, 57) years old. Based on self-sampling, the sensitivity and specificity of POCT for CIN2+ were 100.00% (95%CI: 56.56%-100.00%) and 28.95% (95%CI: 22.97%-35.76%), respectively. Compared with POCT, POCT HPV16/18 test had similar sensitivity and higher specificity of 89.47% (95%CI: 84.30%-93.08%). Self-sampling POCT HPV16/18 test had an AUC of 0.947 (95%CI:0.910-0.985), which was higher than that of careHPV and PCR test. Physician-sampling POCT test had 100.00% sensitivity (95%CI: 64.57%-100.00%) and 55.85% specificity (95%CI: 49.83%-61.70%) for detecting CIN2+. POCT HPV16/18 test had lower sensitivity (71.43%, 95%CI: 35.90%-91.76%) and higher specificity (92.45%, 95%CI: 88.63%-95.06%). POCT HPV16/18 test generally showed similar AUC on both self-collected samples and clinician-collected samples (0.947 vs 0.819, P=0.217). Conclusion: POCT HPV16/18 test is an effective method with relatively high sensitivity and specificity for cervical cancer screening.


Subject(s)
Female , Humans , Pregnancy , Uterine Cervical Dysplasia/diagnosis , Colposcopy , Early Detection of Cancer/methods , Human papillomavirus 16/genetics , Human papillomavirus 18 , Mass Screening/methods , Papillomaviridae , Papillomavirus Infections/diagnosis , Point-of-Care Testing , Sensitivity and Specificity , Uterine Cervical Neoplasms
4.
ABCD (São Paulo, Impr.) ; 34(4): e1637, 2021. tab, graf
Article in English, Portuguese | LILACS | ID: biblio-1360017

ABSTRACT

RESUMO - INTRODUÇÃO: O papilomavírus humano (HPV) é agente das doenças sexualmente transmissíveis de maior prevalência no mundo que estão associadas ao câncer do colo do útero e canal anal. A ação do HPV na carcinogênese colorretal não está ainda estabelecida. OBJETIVO: Estudar a eventual correlação entre a presença do HPV tipo 16 e a expressão gênica da proteína p16INK4a e da oncoproteína E7 de HPV e de seus níveis no tecido do carcinoma colorretal. METODOS: Estudo retrospectivo caso-controle de 79 doentes com carcinoma colorretal divididos em dois grupos: HPV presente e HPV ausente. Foi realizada reação em cadeia da polimerase (PCR), além da hibridização do tipo dot blot para o HPV 16 e o HPV 18 Amostras do tecido colorretal também foram submetidas ao estudo imuno-histoquimico para avaliar o nível tecidual das proteínas E7 e p16INK4a. RESULTADOS: O HPV foi identificado em 36 (45,6%) casos. Não houve diferença significante entre os grupos quanto ao sexo (p=0,056), idade (p=0,1), localização cólica e/ou retal (0,098) e presença do HPV. A expressão gênica da oncoproteína E7 de HPV estava presente em 3,12% dos casos (p=0,9) e a expressão da proteína p16INK4a foi observada em 46,3% (p=0,27) dos indivíduos com detecção do HPV. CONCLUSÃO: A expressão gênica e os níveis teciduais da oncoproteína E7 e da proteína p16INK4a encontrados nos pacientes positivos para o HPV sugerem a ausência de atividade oncogênica do HPV tipo 16 no carcinoma colorretal.


ABSTRACT - BACKGROUND: Human papillomavirus (HPV) is the agent of the most prevalent sexually transmitted diseases in the world associated with cervix and anal canal cancer. The action of HPV on colorectal carcinogenesis is not yet established. OBJECTIVE: This research aimed to study the possible correlation between the presence of HPV16 and the gene expression of p16INK4a protein and HPV E7 oncoprotein and their levels in colorectal carcinoma tissue. METHODS: A retrospective case-control study of 79 patients with colorectal carcinoma was divided into two groups: HPV-positive and HPV-negative. The polymerase chain reaction was performed, in addition to dot-blot hybridization for HPV16 and HPV18. Colorectal tissue samples were also subjected to immunohistochemical study to assess the tissue level of E7 and p16INK4a proteins. RESULTS: HPV was identified in 36 (45.6%) cases. There was no significant difference between groups regarding gender (p=0.056), age (p=0.1), colic and/or rectal location (0.098), and presence of HPV. Gene expression of HPV E7 oncoprotein was present in 3.12% of cases (p=0.9), and p16INK4a protein expression was observed in 46.3% (p=0.27) of those selected with HPV detection. CONCLUSION: Gene expression and tissue levels of E7 oncoprotein and p16INK4a protein found in HPV-positive patients suggest the absence of HPV16 oncogenic activity in colorectal carcinoma.


Subject(s)
Humans , Female , Colorectal Neoplasms/genetics , Colorectal Neoplasms/virology , Cyclin-Dependent Kinase Inhibitor p16/genetics , Papillomavirus Infections/genetics , Papillomavirus E7 Proteins/genetics , DNA, Viral , Case-Control Studies , Retrospective Studies , Human papillomavirus 16/genetics
5.
Braz. j. otorhinolaryngol. (Impr.) ; 86(3): 351-357, May-June 2020. tab, graf
Article in English | LILACS | ID: biblio-1132605

ABSTRACT

Abstract Introduction: Human papilloma virus is an etiological risk factor for a subset of head and neck squamous cell carcinomas. HPV has been proven to be a powerful prognostic biomarker for oropharyngeal cancer, but its role in the larynx has not been explored in depth. The developmental mechanisms of laryngeal carcinomas are quite complex and controlled by various factors. Smoking and alcohol are most important risk factors. Recent studies indicate that HPV infection also plays an important role in larynx carcinomas. HPV related laryngeal carcinomas especially occur at the supraglottic region of larynx. Objective: We aimed to determine the frequency of HPV/protein16 positivity in patients with laryngeal carcinoma and association of HPV and/or p16 positivity with variables such as age, sex, smoking habits, tumor localization, lymph node metastasis, recurrence and survival in advanced stage laryngeal carcinoma in our study. Methods: This retrospective study included 90 patients with advanced laryngeal carcinoma. The Control group was 10 normal larynx mucosa specimens. The presence of HPV was investigated polyclonally by polymerase chain reaction, and protein16 with immunohistochemical method. In HPV positive cases, the presence of HPV types 16, 18 were evaluated by polymerase chain reaction. Demographic features of patients were noted. Patient survival and association with HPV/protein16 was determined. Results: Polyclonal HPV positivity was detected in 11 (12.2%) of 90 cases. Out of these 11 cases, HPV 16 was positive in 6, HPV 18 in 4, and both HPV 16 and 18 were positive in 1. In 18 (20%) of the cases, p16 was positive. Six of the cases (6.6%) had both HPV and protein16 positivity. In cases where protein16 alone or HPV and protein16 were co-positive, alcohol use was less and the tumor was found more likely to be localized in the supraglottic area. These ratios were statistically significant. Supraglottic localization of tumor was determined to be increased in protein16 positive cases. The correlation between protein16 positivity and supraglottic area location was determined to be statistically significant (p= 0.011). 55.6% of protein16 positive cases was located in the supraglottic region, 33.3% was glottic and 11.1% was transglottic. Although life expectancy over 5 years were numerically higher in HPV and protein16 positive cases, this was not found to be statistically significant. There was no statistically significant relationship between HPV positivity and mean age, differentiation, smoking and alcohol use, tumor progression, lymph node metastasis, localization, recurrence, cause of mortality and treatment methods in our study. The mean follow-up period of our patients was 6.7 years. Conclusion: The close relationship between HPV and oropharyngeal squamous cell carcinoma could not be shown in larynx malignancy in many studies, including our study. Our findings support a limited role of HPV in laryngeal carcinogenesis. Protein16 is not a reliable surrogate for HPV status in laryngeal cancers and is not a predictor of laryngeal cancer survival. Supraglottic localization of tumor was determined to be increased in protein16 positive cases. The correlation between protein16 positivity and supraglottic area location was determined to be statistically significant. There is a need for more populated clinical trials, where neoplastic proliferation is better demonstrated and the accuracy of the results obtained is supported by different techniques.


Resumo Introdução: O papilomavírus humano é um fator de risco etiológico para um subconjunto de carcinoma espinocelular de cabeça e pescoço. Tem sido demonstrado que o HPV é um poderoso biomarcador prognóstico para o câncer de orofaringe, mas seu papel na laringe ainda não foi explorado em profundidade. Os mecanismos de desenvolvimento dos carcinomas de laringe são bastante complexos e controlados por vários fatores. Tabagismo e álcool são os fatores de risco mais importantes. Estudos recentes indicam que a infecção pelo HPV também desempenha um papel importante nos carcinomas da laringe. Os carcinomas laríngeos relacionados ao HPV ocorrem especialmente na região supraglótica. Objetivo: Nosso objetivo foi determinar a frequência da positividade para o HPV / proteína 16 em pacientes com carcinoma da laringe e a associação da positividade para o HPV e /ou proteína 16 com variáveis como idade, sexo, tabagismo, localização do tumor, metástase linfonodal, recidiva e sobrevivência de carcinoma da laringe em estágio avançado em nosso estudo. Método: Este estudo retrospectivo incluiu 90 pacientes com carcinoma laríngeo avançado. O grupo controle incluiu 10 amostras de mucosa laríngea normal. A presença de HPV foi inves-tigada por anticorpo policlonal através de reação de polimerase em cadeia e a proteína 16 por método imunohistoquímico. Nos casos positivos para o HPV, a presença dos tipos 16 e 18 do foi avaliada por reação de polimerase em cadeia. As características demográficas dos pacientes foram observadas. A sobrevida dos pacientes e a associação com HPV / proteína 16 foram determinadas. Resultados: A positividade com anticorpo policlonal do HPV foi detectada em 11 (12,2%) dos 90 casos. Desses 11 casos, o HPV 16 foi positivo em 6, o HPV 18 em 4 e o HPV 16 e 18 foram positivos em 1. Em 18 (20%) dos casos, a proteína 16 foi positiva. Seis dos casos (6,6%) apresentaram positividade para HPV e proteína16. Nos casos positivos apenas para a proteína 16 ou quando HPV e a proteína 16 foram co-positivos, a ingestão de álcool foi menor e o tumor apresentou maior probabilidade de estar localizado na área supraglótica. Essas proporções foram estatisticamente significantes. A localização supraglótica do tumor foi maior em casos positivos para proteína 16. A correlação entre positividade para proteína 16 e localização da área supraglótica foi estatisticamente significante (p = 0,011). Dos casos positivos para proteína 16, 55,6% foram supraglóticos, 33,3% glóticos e 11,1% transglóticos. Embora a expectativa de vida acima de 5 anos tenha sido numericamente maior nos casos positivos para HPV e proteína 16, isso não foi estatisticamente significante. Não houve relação estatisticamente significante entre positividade do HPV e média de idade, diferenciação, tabagismo e uso de álcool, progressão tumoral, metástase linfonodal, localização, recidiva, causa de mortalidade e métodos de tratamento em nosso estudo. O período médio de seguimento de nossos pacientes foi de 6,7 anos. Conclusão: A estreita relação entre HPV e carcinoma espinocelular orofaríngeo não pôde ser demonstrada na laringe em muitos estudos, inclusive no nosso estudo. Nossos achados confirmam um papel limitado do HPV na carcinogênese da laringe. A proteína 16 não é um substituto confiável para o status do HPV nos cânceres de laringe e não é preditor da sobrevida do câncer de laringe. A localização supraglótica do tumor foi maior em casos positivos para proteína16. A correlação entre positividade para proteína 16 e localização na área supraglótica foi determinada como estatisticamente significante. Há necessidade de ensaios clínicos com amostras maiores, nos quais a proliferação neoplásica seja melhor demonstrada e a precisão dos resultados obtidos seja apoiada por diferentes técnicas.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Aged, 80 and over , Young Adult , Laryngeal Neoplasms/blood , Laryngeal Neoplasms/virology , Cyclin-Dependent Kinase Inhibitor p16/blood , Human papillomavirus 16/genetics , Human papillomavirus 18/genetics , Prognosis , Laryngeal Neoplasms/mortality , Retrospective Studies , Risk Factors , Neoplasm Staging
6.
Mem. Inst. Invest. Cienc. Salud (Impr.) ; 17(1): 6-15, abr. 2019. ilus, tab
Article in Spanish | LILACS, BDNPAR | ID: biblio-1007859

ABSTRACT

En Paraguay la incidencia de cáncer de cuello uterino (CCU) es superior a las observadas en otros países de la región. El agente etiológico asociado al CCU es el virus papiloma humano (VPH), esencialmente tipos de alto riesgo oncogénicos. El objetivo es describir aspectos epidemiológicos de la infección genital por el virus papiloma humano de alto riesgo (VPH-AR) en mujeres de 25 a 64 años que consultaron en servicios de Patología Cervical del MSPyBS, de mayo a diciembre de 2013. Se utilizó el Cobas 4800 HPV Test (Roche) que permite la detección individual de VPH-16 y VPH-18 y un pool de otros VPH-AR que incluye 12 genotipos de alto riesgo. Los otros VPH-AR fueron tipificados por hibridación reversa en línea (RLB). Entre las 495 mujeres incluidas, se detectaron 72 casos positivos (14,5%) de VPH-AR. Se identificaron 19 tipos virales; siendo el más frecuente VPH-16 (2,1%), seguido del VPH-31, 33, 58 y 66; el VPH-18 aparece en sexto lugar. Este trabajo aporta los primeros datos sobre la implementación de técnicas moleculares para detección y tipificación de VPH como parte del sistema de salud pública de Paraguay. El predominio de VPH-16, confirma su amplia circulación a nivel mundial y dado su mayor potencial oncogénico, representa una alerta a considerar, en especial en las mujeres mayores de 30 años portadoras de una infección persistente. Estos resultados apoyan la importancia de la implementación criteriosa y la utilización apropiada de las pruebas moleculares actualmente disponibles para la prevención y control del CCU(AU)


Subject(s)
Humans , Female , Adult , Middle Aged , Papillomaviridae/genetics , Uterine Cervical Neoplasms/epidemiology , Uterine Cervical Neoplasms/virology , Papillomavirus Infections/epidemiology , Papillomavirus Infections/virology , Paraguay/epidemiology , Cross-Sectional Studies , Human papillomavirus 16/genetics , Human papillomavirus 18/genetics , Genotyping Techniques
7.
Mem. Inst. Invest. Cienc. Salud (Impr.) ; 16(3): 6-12, dic. 2018. tab, ilus
Article in Spanish | LILACS, BDNPAR | ID: biblio-998219

ABSTRACT

El cáncer de cuello uterino es el segundo cáncer femenino más común a nivel mundial. El agente causal es el virus de papiloma humano (VPH). Se han identificado 13 tipos de virus de papiloma humano de alto riesgo oncogénico (VPH-AR), entre los cuales el VPH 16 y VPH 18 son los más frecuentemente detectados en cáncer de cuello uterino, siendo en Paraguay detectados en el 70% de casos de cáncer invasor. Por ello, el objetivo fue estandarizar y determinar el límite de detección de una técnica de PCR convencional para la detección de VPH 16 y 18. Para la detección de ADN de VPH 16 y 18, se observaron mejores resultados con 2mM de MgCl2 y 60°C para la temperatura de alineamiento. El límite de detección para las PCR fue de 14,6x10-11ng/µL para VPH 16 y 21,7x10-12ng/µL para VPH 18. Este trabajo servirá de base a otros estudios de detección e identificación de estos tipos virales por PCR, con miras a identificar un grupo de mujeres positivas para VPH-AR que poseen mayor riesgo de desarrollo de lesión y cáncer de cuello uterino y precisan de un seguimiento más cercano(AU


Cervical cancer is the second most common female cancer worldwide. It is caused by the human papilloma virus (HPV). Thirteen genotypes of high oncogenic risk human papilloma viruses (HPV-HR) have been identified, among which types 16 and 18 are the most frequently detected in cervical cancer. In Paraguay, they are detected in 70% of the invasive cancer cases. Therefore, the objective was to standardize and determine the detection limit of a conventional PCR technique for the detection of HPV 16 and 18. Better results were observed with 2mM MgCl2 and 60°C for the alignment temperature in detection of HPV 16 and 18 DNA. The limit of detection was 14.6x10-11ng/µL for HPV 16 and 21.7x10-12ng/µL for HPV 18. This work will help other studies for the detection and identification of these viral types by PCR in order to identify a group of HPV-HR positive women who have higher risk for the development of lesions and cervical cancer and need a closer follow-up(AU)


Subject(s)
Humans , Female , Uterine Cervical Neoplasms/virology , Polymerase Chain Reaction/methods , Papillomavirus Infections/virology , Human papillomavirus 16/genetics , Human papillomavirus 18/genetics , Base Sequence , Genome, Viral , DNA Primers , Electrophoresis, Polyacrylamide Gel , Limit of Detection
9.
Mem. Inst. Oswaldo Cruz ; 112(7): 492-498, July 2017. tab
Article in English | LILACS | ID: biblio-841811

ABSTRACT

BACKGROUND Increasing evidence suggests that human papillomavirus (HPV) intratype variants (specific lineages and sublineages) are associated with pathogenesis and progression from HPV infection to persistence and the development of cervical cancer. OBJECTIVES This study aimed to verify the prevalence of HPV infection and distribution of HPV types and HPV16 variants in southern Brazil in women with normal cytology or intraepithelial lesions. METHODS HPV typing was determined by L1 gene sequencing. To identify HPV16 variants, the LCR and E6 regions were sequenced, and characteristic single nucleotide variants were identified. FINDINGS A total of 445 samples were studied, with 355 from cervical scrapes and 90 from cervical biopsies. HPV was detected in 24% and 91% of these samples, respectively. The most prevalent HPV types observed were 16 (cervical, 24%; biopsies, 57%) and 58 (cervical, 12%; biopsies, 12%). Seventy-five percent of the HPV16-positive samples were classified into lineages, with 88% defined as lineage A, 10% as lineage D, and 2% as lineage B. MAIN CONCLUSIONS This study identified a high frequency of European and North American HPV16 lineages, consistent with the genetic background of the human population in southern Brazil.


Subject(s)
Humans , Female , Adult , Genetic Variation/genetics , DNA, Viral/genetics , Uterine Cervical Neoplasms/virology , Papillomavirus Infections/virology , Human papillomavirus 16/genetics , Socioeconomic Factors , Brazil , Uterine Cervical Dysplasia , Polymerase Chain Reaction , Cross-Sectional Studies
10.
Braz. j. otorhinolaryngol. (Impr.) ; 83(1): 38-44, Jan.-Feb. 2017. tab
Article in English | LILACS | ID: biblio-839410

ABSTRACT

Abstract Introduction Molecular studies about carcinomas of the oral cavity and oropharynx demonstrate the presence of human papilomavirus genome in these tumors, reinforcing the participation of human papilomavirus in oral carcinogenesis. Objectives This study aimed to determine the prevalence of human papilomavirus and genotype distribution of HPV16 and HPV18 in oral cavity and oropharynx carcinomas, as well as their association with clinical characteristics of the tumors. Methods This is a retrospective study, with clinical data collected from 82 patients. Human papilomavirus detection was conducted on specimens of oral cavity and oropharynx carcinomas included in paraffin blocks. Patients were assisted in a cancer reference center, in the central region of Brazil, between 2005 and 2007. Polymerase chain reaction was used for the detection and genotyping of human papilomavirus. Results Among the patients evaluated, 78% were male. The average age of the group was about 58 years. Risk factors, such as smoking (78%) and alcohol consumption (70.8%) were recorded for the group. HPV DNA was detected in 21 cases (25.6%; 95% confidence interval 16.9–36.6) of which 33.3% were HPV16 and 14.3% were HPV18. The presence of lymph node metastases and registered deaths were less frequent in human papilomavirus positive tumors, suggesting a better prognosis for these cases; however, the differences between the groups were not statistically significant. Conclusion The results obtained in the present study, with respect to the presence of the high-risk HPV16 and HPV18 genotypes, highlight the importance of human papilomavirus vaccination in the control of oral cavity and oropharynx carcinomas.


Resumo Introdução Estudos moleculares sobre carcinomas da cavidade oral e orofaringe demonstram a presença do genoma do papilomavírus humano (HPV) nesses tumores, o que enfatiza a participação do HPV na carcinogênese oral. Objetivos Determinar a prevalência de HPV e a distribuição genotípica de HPV16 e HPV18 nos carcinomas de cavidade oral e orofaringe, bem como sua associação com as características clínicas dos tumores. Método Estudo retrospectivo, com dados clínicos coletados de 82 pacientes. A detecção de HPV foi feita em amostras de carcinomas de cavidade oral e orofaringe incluídos em blocos de parafina. Os pacientes foram atendidos em um centro de referência para tratamento do câncer, na região central do Brasil, entre 2005 e 2007. Foi usada a reação em cadeia de polimerase (PCR) para a detecção e genotipagem do HPV. Resultados Entre os pacientes avaliados, 78% eram homens. A média de idade do grupo era de 58 anos. Fatores de risco como o tabagismo (78%) e consumo de álcool (70,8%) foram registrados para o grupo. HPV DNA foi detectado em 21 casos (25,6%; IC de 95%, 16,9-36,6), dos quais 33,3% eram HPV16 e 14,3% eram HPV18. A presença de metástases em linfonodos e os óbitos registrados foram menos frequentes em tumores positivos para HPV, o que sugere melhor prognóstico para esses casos; contudo, as diferenças entre os grupos não foram estatisticamente significantes. Conclusão Os resultados obtidos no presente estudo, com respeito à presença de genótipos de alto risco de HPV16 e HPV18, destacam a importância da vacinação para HPV no controle dos carcinomas de cavidade oral e orofaringe.


Subject(s)
Humans , Male , Female , Middle Aged , Oropharyngeal Neoplasms/virology , Papillomavirus Infections/genetics , Papillomavirus Infections/virology , Human papillomavirus 16/genetics , Human papillomavirus 18/genetics , Mouth/virology , Brazil , DNA, Viral/genetics , Polymerase Chain Reaction , Retrospective Studies , Risk Factors , Human papillomavirus 18/isolation & purification , Genotype
11.
J. appl. oral sci ; 24(4): 397-403, July-Aug. 2016. tab, graf
Article in English | LILACS, BBO | ID: lil-792601

ABSTRACT

ABSTRACT Objective The objective of this study was to clarify differences regarding HPV16 infection and gene amplification between the oral cavity and oropharynx in healthy individuals. Material and Methods The subjects were 94 healthy asymptomatic individuals (41 males, 53 females; mean age 58.6 years, range 16-97 years) who visited the Department of Oral and Maxillofacial Reconstructive Surgery of the Hiroshima University Hospital from 2014 to 2015. Oral epithelial cells were collected from oral rinse and pharynx gargle samples and placed in saline. The human endogenous retrovirus gene ERV3-1 was used as a reference to estimate the number of human cells in each sample. DNA samples were extracted from approximately 10,000 human cells and tested for HPV16 DNA by PCR using a type-specific primer. Similarly, we analyzed the HPV16 viral copy number in HPV16-positive cases using real-time PCR to examine genomic amplification. Results The percentage of HPV16-positive cases was higher in the gargle (28.7%) as compared to the rinse (16.0%) samples. In the oral rinse samples, males (26.8%) showed a significantly higher rate of HPV16 than females (7.5%) (P=0.021). Importantly, in older subjects (aged 60-89 years), gargle samples showed a significantly higher rate of HPV16 (33.3%) than oral rinse samples (13.7%) (P=0.034). The average number of viral copies was approximately 8 times higher in the gargle than in the oral rinse samples (0.16±0.27 vs. 1.35±1.26 copy numbers per cell), a significant difference (P<0.001). Conclusion Our findings suggest that the oropharynx is more susceptible to HPV16 infection as compared to the oral cavity, while HPV16 gene amplification is also more commonly found in the oropharynx.


Subject(s)
Humans , Male , Female , Adolescent , Adult , Middle Aged , Aged , Aged, 80 and over , Young Adult , Oropharynx/virology , Gene Amplification/physiology , Papillomavirus Infections/epidemiology , Papillomavirus Infections/virology , Human papillomavirus 16/genetics , Mouth/virology , Time Factors , DNA, Viral , Cell Count , Prevalence , Risk Factors , Age Factors , DNA Copy Number Variations , Real-Time Polymerase Chain Reaction , Japan/epidemiology
12.
Journal of Gynecologic Oncology ; : e56-2016.
Article in English | WPRIM | ID: wpr-115238

ABSTRACT

OBJECTIVE: Infection with high-risk genotypes of human papillomavirus (HR-HPV) is the major cause of invasive cervical cancers. HPV-16 and HPV-18 are known to be responsible for two-thirds of all invasive cervical carcinomas, followed by HPV-45, -31, and -33. Current guidelines only differentiate HPV-16/18 (+) by recommending direct colposcopy for treatment. We tried to evaluate whether there are differences in risk among 12 non-16/18 HR-HPV genotypes in this study. METHODS: The pathology archive database records of 1,102 consecutive gynecologic patients, who had results for cervical cytology and histology and for HPV testing, as determined by HPV 9G DNA chip, were reviewed. RESULTS: Among the 1,102 patients, 346 were non-16/18 HR-HPV (+) and 231 were HPV-16/18 (+). We calculated the odds ratios for ≥cervical intraepithelial neoplasia 2 (CIN 2) of 14 groups of each HR-HPV genotype compared with a group of HR-HPV (–) patients. Based on the odds ratio of each genotype, we divided patients with non-16/18 HR-HPV genotypes (+) into two groups: HPV-31/33/35/45/52/58 (+) and HPV-39/51/56/59/66/68 (+). The age-adjusted odds ratios for ≥CIN 2 of the HPV-31/33/35/45/52/58 (+) and HPV-39/51/56/59/66/68 (+) groups compared with a HR-HPV (–) group were 11.9 (95% CI, 7.6 to 18.8; p<0.001) and 2.4 (95% CI, 1.4 to 4.3; p<0.001), respectively, while that of the HPV-16/18 (+) group was 18.1 (95% CI, 11.6 to 28.3; p=0.003). CONCLUSION: The 12 non-16/18 HR-HPV genotypes can be further categorized (HPV-31/33/35/45/52/58 vs. HPV-39/51/56/59/66/68) by risk stratification. The HPV-31/33/35/45/52/58 genotypes might need more aggressive action. Large scale clinical trials or cohort studies are necessary to confirm our suggestion.


Subject(s)
Adult , Female , Humans , Middle Aged , Uterine Cervical Dysplasia/virology , Colposcopy , DNA, Viral/analysis , Genotype , Human papillomavirus 16/genetics , Human papillomavirus 18/genetics , Papanicolaou Test , Papillomaviridae/genetics , Papillomavirus Infections/virology , Risk Factors , Uterine Cervical Neoplasms/virology , Vaginal Smears
13.
Journal of Korean Medical Science ; : 371-375, 2016.
Article in English | WPRIM | ID: wpr-85726

ABSTRACT

Further understanding of male human papillomavirus (HPV) infection is necessary to prevent infection in men, as well as transmission to women. In our current study, we investigated patterns of HPV infection and genotype distributions in male genital warts using the Anyplex II HPV28 Detection kit. We reviewed the medical records of 80 male patients who presented to 5 neighborhood clinics in Ulsan, Korea, for the treatment of genital warts between April 2014 and January 2015. All patients underwent HPV genotyping. The prevalence and characteristics of HPV infection were analyzed, and the patterns of HPV infection according to age were assessed. Among the study patients, 13 (16.3%) were negative for HPV infection, 46 (57.3%) were infected with low-risk HPV, and 21 (26.3%) were infected with high-risk HPV. Patients with multiple HPV infection were more likely to have high-risk HPV infection (P = 0.001). The prevalence of HPV infection was much higher in samples obtained by tissue excision due to a definite lesion (P = 0.001). There were no differences in high-risk HPV infection (P = 0.459), multiple HPV infection (P = 0.185), and recurrence at diagnosis (P = 0.178) according to age. HPV-6 and HPV-11 were the most common type overall (39.7% and 13.8%, respectively). HPV-16 and HPV-18 were the most common high-risk infections (both 3.4%). HPV infection is not only commonly encountered in male genital warts, but is also accompanied by high-risk HPV and multiple infections.


Subject(s)
Adult , Humans , Male , Middle Aged , Condylomata Acuminata/epidemiology , DNA, Viral/genetics , Genotype , Human papillomavirus 11/genetics , Human papillomavirus 16/genetics , Human papillomavirus 18/genetics , Human papillomavirus 6/genetics , Prevalence , Real-Time Polymerase Chain Reaction , Republic of Korea/epidemiology , Retrospective Studies , Risk Factors
14.
Journal of Gynecologic Oncology ; : e2-2016.
Article in English | WPRIM | ID: wpr-21464

ABSTRACT

OBJECTIVE: This study was conducted using the human papillomavirus (HPV) DNA chip test (HDC), in order to determine whether the HPV genotype is a predictor of residual disease in a subsequent hysterectomy following a loop electrosurgical excision procedure (LEEP) for cervical intraepithelial neoplasia (CIN) 3. METHODS: Between January 2002 and February 2015, a total of 189 patients who underwent a hysterectomy within 6 months of LEEP caused by CIN 3 were included in this study. We analyzed their epidemiological data, pathological parameters, high-risk HPV (HR-HPV) load as measured by the hybrid capture II assay, and HR-HPV genotype as measured by the HDC. A logistic regression model was used to analyze the relationship between covariates and the probability of residual disease in subsequent hysterectomy specimens. RESULTS: Of the 189 patients, 92 (48.7%) had residual disease in the hysterectomy specimen, CIN 2 in seven patients, CIN 3 in 79 patients, IA1 cancer in five patients, and IA2 cancer in one patient. Using multivariate analysis, the results were as follows: cone margin positivity (odds ratio [OR], 2.43; 95% CI, 1.18 to 5.29; p or =220 relative light unit (OR, 2.98; 95% CI, 1.38 to 6.43; p<0.01), positive endocervical cytology (OR, 8.97; 95% CI, 3.81 to 21.13; p<0.001), and HPV-16 or HPV-18 positivity (OR, 9.07; 95% CI, 3.86 to 21.30; p<0.001). CONCLUSION: The HPV-16 or HPV-18 genotype is a reliable predictive factor of residual disease in a subsequent hysterectomy following a LEEP for CIN 3.


Subject(s)
Adult , Aged , Aged, 80 and over , Female , Humans , Middle Aged , Uterine Cervical Dysplasia/surgery , Electrosurgery/methods , Genotype , Genotyping Techniques/methods , Human papillomavirus 16/genetics , Human papillomavirus 18/genetics , Hysterectomy , Neoplasm, Residual , Papillomavirus Infections/virology , Prognosis , Retrospective Studies , Uterine Cervical Neoplasms/surgery , Viral Load
15.
Journal of Korean Medical Science ; : 32-37, 2014.
Article in English | WPRIM | ID: wpr-53760

ABSTRACT

The epidemiology on human papillomavirus (HPV) among human immunodeficiency virus (HIV)-infected women in Korea is not well established. A retrospective study was conducted to determine the prevalence and genotype distribution of HPV infection among HIV-infected women in Korea. HPV DNA genotype and cervical cytology were examined in 60 HIV-positive women and 1,938 HIV-negative women. HPV genotypes were analyzed by using a HPV DNA chip. HIV-infected women had higher prevalence of high-risk HPV (hr-HPV) infection (30% vs 4.9%, adjusted odds ratio [AOR], 6.96; 95% confidence interval [CI], 3.63-13.34, P<0.001) and abnormal cervical cytology (18.3% vs 1.8%, AOR, 10.94; 95% CI, 5.18-23.1, P<0.001) compared with controls. The most common hr-HPV genotype detected in HIV-infected women was HPV 16 (10%), followed by 18 (6.7%) and 52 (5%). Prevalence of quadrivalent vaccine-preventable types (HPV 6, 11, 16, and 18) was 21.7% and 2.3% in HIV-positive women and HIV-negative women, respectively. Age was a significant risk factor for hr-HPV infection in HIV-infected women (P=0.039). The presence of hr-HPV was significantly associated with abnormal cervical cytology (P<0.001). These findings suggest that HPV testing for cervical cancer screening in HIV-infected women would be necessary, particularly among young age group.


Subject(s)
Adult , Female , Humans , Middle Aged , Age Factors , Cervix Uteri/virology , DNA Probes, HPV , DNA, Viral/genetics , Genotype , HIV Infections/complications , HIV-1/genetics , Human papillomavirus 11/genetics , Human papillomavirus 16/genetics , Human papillomavirus 18/genetics , Human papillomavirus 6/genetics , Papillomavirus Infections/complications , Prevalence , Republic of Korea/epidemiology , Retrospective Studies , Risk Factors , Uterine Cervical Neoplasms/epidemiology
16.
Annals of Laboratory Medicine ; : 201-205, 2012.
Article in English | WPRIM | ID: wpr-80823

ABSTRACT

BACKGROUND: We evaluated the performance of various commercial assays for the molecular detection of human papillomavirus (HPV); the recently developed AdvanSure HPV Screening real-time PCR assay (AdvanSure PCR) and the Abbott RealTime High Risk HPV PCR assay (Abbott PCR) were compared with the Hybrid Capture 2 HPV DNA Test (HC2). METHODS: All 3 tests were performed on 177 samples, and any sample that showed a discrepancy in any of the 3 tests was genotyped using INNO-LiPA HPV genotyping and/or sequencing. On the basis of these results, we obtained a consensus HPV result, and the performance of each test was evaluated. We also evaluated high-risk HPV 16/18 detection by using the 2 real-time PCR assays. RESULTS: Among the 177 samples, 65 were negative and 75 were positive in all 3 assays; however, the results of the 3 assays with 37 samples were discrepant. Compared with the consensus HPV result, the sensitivities and specificities of HC2, AdvanSure PCR, and Abbott PCR were 97.6%, 91.7%, and 86.9% and 83.9%, 98.8%, and 100.0%, respectively. For HPV type 16/18 detection, the concordance rate between the AdvanSure PCR and Abbott PCR assays was 98.3%; however, 3 samples were discrepant (positive in AdvanSure PCR and negative in Abbott PCR) and were confirmed as HPV type 16 by INNO-LiPA genotyping and/or sequencing. CONCLUSIONS: For HPV detection, the AdvanSure HPV Screening real-time PCR assay and the Abbott PCR assay are less sensitive but more specific than the HC2 assay, but can simultaneously differentiate type 16/18 HPV from other types.


Subject(s)
Adult , Aged , Female , Humans , Middle Aged , Young Adult , Cervix Uteri/pathology , DNA, Viral/analysis , Genotype , Human papillomavirus 16/genetics , Human papillomavirus 18/genetics , Papillomaviridae/genetics , Papillomavirus Infections/diagnosis , Reagent Kits, Diagnostic , Sensitivity and Specificity
17.
Journal of Korean Medical Science ; : 1091-1097, 2012.
Article in English | WPRIM | ID: wpr-157111

ABSTRACT

The development of a prophylactic vaccine that targets human papillomaviruses (HPV) 6, 11, 16, and 18 to prevent cervical cancer has increased interest in the ethnic and geographical distributions of HPV genotypes. We investigated HPV prevalence and type distribution by restriction fragment mass polymorphism (RFMP) testing a total of 60,775 specimens (aged 18-79 yr, median 44) taken from liquid-based cytology. Overall HPV positive rate of total patients was 34.2%. Among the positive patients, 87.7% was single type infections, and 12.3% was multiple HPV types. HPV-16 was the most prevalent genotype observed in 2,307 (26.0%), followed by type 52 in 2,269 (25.5%), type 58 in 1,090 (12.3%), type 18 in 633 (7.1%), type 56 in 436 (4.9%). The pattern of high risk-HPV positive rate according to age showed U-shape with a peak in HPV prevalence among women less than 30 yr of age, and a second peak among the older females aged 70 to 79 yr. The leading four high-risk HPV genotypes were HPV-16, HPV-52, HPV-58, and HPV-18 in descending order. In conclusion, this study provides the most representative prevalence and type-specific distribution of HPV among Korean women, and demonstrates that the epidemiology of HPV infection is different from that of other regions of the world.


Subject(s)
Adolescent , Adult , Aged , Female , Humans , Middle Aged , Young Adult , Age Factors , Asian People , DNA, Viral/analysis , Genotype , Human papillomavirus 16/genetics , Human papillomavirus 18/genetics , Papillomavirus Infections/epidemiology , Polymorphism, Restriction Fragment Length , Prevalence , Republic of Korea/epidemiology , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
18.
EJB-Egyptian Journal of Biochemistry and Molecular Biology [The]. 2011; 29 (2): 343-360
in English | IMEMR | ID: emr-117199

ABSTRACT

It was relevant to assess the impact of a HPV-16 [human papillomavirus-16] which is a high-risk genotype on head and neck cancers and its relation to CIAP-2 expression [Cellular Inhibitor of apoptosis-2]. Tissue samples were taken from patients diagnosed as head and neck cancer. All samples were subjected to qualitative polymerase chain reaction [PCR] analysis for HPV, qualitative and semi-quantitative reverse transcription polymerase chain reaction [RT-PCR] of CIAP-2. There was a significant association between HPV-16 and CIAP2 positivity and head and neck tumors. CIAP-2 expression in malignant tissues was highly associated with HPV-16 infection at sensitivity 73.9% and absolute specificity


Subject(s)
Humans , Human papillomavirus 16/genetics , Polymerase Chain Reaction/methods , Sensitivity and Specificity
19.
Article in English | IMSEAR | ID: sea-135934

ABSTRACT

Background & objectives: Cervical cancer is the second most frequent cancer among females worldwide, especially human papilloma viruses (HPV) types 16 and 18. In viral systems the identification of serological markers would facilitate the diagnosis of HPV infections and virus-related disease. The aim of the present investigation was to determine and search for serologic markers in cervical cancer patients associated with HPV. Methods: A total of 58 Iranian women with invasive cervical carcinoma including adenocarcinoma and squamous cell carcinoma (SCC) were included. Serum antibody response to HPV infections in patients was detected by Western blot and ELISA techniques based on recombinant HPV16E7 and the N-terminal and C-terminal fragments of gp96 (NT-gp96 and CT-gp96) proteins. These recombinant proteins were expressed in Escherichia coli as a His-tag protein and purified using affinity chromatography. Results: The ELISA results indicated that patients with high antibody response to HPV16E7 had significant seroreactivity to CT-gp96 fragment. In Western blot analysis, a strong association between anti-E7, anti-NT-gp96 and anti-CT-gp96 reactivity and cervical cancer was obtained using purified recombinant proteins. In adenocarcinoma cases, no significant difference was observed in seroreactivities between normal and patients. Interpretation & conclusions: The evaluation of cervical cancer patients' seroreactivities against three recombinant proteins (rE7, rNT-gp96 and rCT-gp96) showed significantly higher levels of these markers in SCC only, but not in adenocarcinoma and control groups. Also, the usage of both techniques (ELISA and Western blotting) can provide more reliable tools for diagnosis of cervical cancer.


Subject(s)
Adult , Aged , Antibodies, Neoplasm/blood , Antibodies, Viral/blood , Base Sequence , DNA Primers/genetics , Female , Human papillomavirus 16/genetics , Human papillomavirus 16/immunology , Humans , Iran , Membrane Glycoproteins/genetics , Membrane Glycoproteins/immunology , Middle Aged , Papillomavirus E7 Proteins/genetics , Papillomavirus E7 Proteins/immunology , Recombinant Proteins/immunology , Biomarkers, Tumor/immunology , Uterine Cervical Neoplasms/immunology , Young Adult
20.
Article in English | IMSEAR | ID: sea-135887

ABSTRACT

Background & objective: Recombinant DNA technology allows expression of the human papillomavirus (HPV) major capsid protein (L1) in heterologous expression systems and the recombinant protein self assembles to virus-like particles (VLP). We took up this study to produce recombinant HPV-16 L1 in yeast, establish the process of recombinant L1 derived VLP preparation and develop an ELISA using VLP as the antigen for serological evaluation of anti HPV-16 L1 antibody status. Methods: Complete HPV-16 L1 was amplified from genomic DNA of an esophageal cancer biopsy, cloned and the protein was expressed in a galactose-inducible Saccharomyces cerevisiae expression system. Self assembled VLP was purified by a two-step density gradient centrifugation process and the VLP preparation used to test its suitability in developing an ELISA. Results: The recombinant protein was predominantly a ~55 KD species with distinct immunoreactivity and formed VLP as confirmed by electron microscopy. An ELISA using the VLP showed its efficacy in appropriate immunoreactivity to serum/plasma IgG. Interpretation & conclusions: Recombinant HPV-16 capsid protein derived VLP was produced and the VLP antigen based ELISA can be used to probe serological association of HPV with different clinical conditions. The VLP technology can be improved further and harnessed for future vaccine development efforts in the country.


Subject(s)
Antibodies, Viral/analysis , Antigens, Viral/biosynthesis , Antigens, Viral/genetics , Capsid Proteins/biosynthesis , Capsid Proteins/genetics , Capsid Proteins/immunology , Enzyme-Linked Immunosorbent Assay , Human papillomavirus 16/genetics , Human papillomavirus 16/immunology , Human papillomavirus 16/ultrastructure , Humans , Oncogene Proteins, Viral/biosynthesis , Oncogene Proteins, Viral/genetics , Oncogene Proteins, Viral/immunology , Recombinant Proteins/biosynthesis , Recombinant Proteins/genetics , Recombinant Proteins/immunology , Saccharomyces cerevisiae/genetics
SELECTION OF CITATIONS
SEARCH DETAIL